Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny particles in blood may signal hidden heart risk in hypertensive children

NCT ID NCT07728643

Knowledge-focused Sponsor: Josip Juraj Strossmayer University of Osijek Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This study investigates whether microscopic particles shed from blood vessels, called endothelial extracellular vesicles, can serve as early warning signs of blood vessel damage in children with newly diagnosed, untreated high blood pressure. Researchers will compare these particles between children with normal blood pressure and those with hypertension, and check how they relate to blood pressure levels and blood vessel function. The goal is to better understand how high blood pressure injures vessels early in life and to explore non-invasive ways to predict future heart risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If certain particles in the blood reliably signal early blood vessel damage, doctors could one day use a simple blood test to assess heart risk in children with high blood pressure.
What could go wrong
This is a small, early observational study, not a treatment trial. It may not find clear links, and any future test would need much larger studies to prove useful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include children and adolescents recruited from the outpatient clinics of the Department of Pediatrics, University Hospital Centre Osijek, Croatia. Participants will comprise normotensive children and adolescents and those with newly diagnosed, previously untreated primary hypertension, classified according to current pediatric hypertension guidelines.

Ages

6 to 17 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children and adolescents aged 6-17 years. * Written informed consent from a parent or legal guardian and assent from the participant when appropriate. * Normotensive status or newly diagnosed, previously untreated primary hypertension according to current pediatric hypertension guidelines. * Ability to comply with study procedures. Exclusion Criteria: * Secondary hypertension. * Previous antihypertensive treatment. * Congenital heart disease or other significant cardiovascular disease. * Diabetes mellitus. * Chronic kidney disease. * Autoimmune or chronic inflammatory disease. * Acute infection at the time of enrollment. * Malignancy. * Use of medications known to affect endothelial function. * Inability to comply with study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endothelial dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endothelial dysfunction Pediatric hypertension Primary hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Medicine Osijek

    RECRUITING

    Osijek, 31000, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.